Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEEBACIN vs MYAMBUTOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TEEBACIN is a combination of isoniazid and rifampin. Isoniazid inhibits mycolic acid synthesis in mycobacterial cell wall, while rifampin inhibits bacterial DNA-dependent RNA polymerase.
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
Treatment of tuberculosis (first-line therapy in combination with other antituberculosis agents)
Treatment of pulmonary tuberculosis in combination with other antituberculosis agents,Treatment of extrapulmonary tuberculosis
1350 mg orally twice daily with food.
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; clinical context: reduced dosing interval required in renal impairment (e.g., every 12-24 hours for Cr Cl <30 m L/min)
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
Isoniazid is metabolized primarily by N-acetyltransferase 2 (NAT2) in the liver. Rifampin is metabolized via deacetylation and undergoes extensive enterohepatic circulation; it is a potent inducer of CYP3A4 and other CYP450 enzymes.
Partially metabolized in the liver via dealkylation to an aldehyde intermediate, which is further oxidized to a dicarboxylic acid. Approximately 50% of the drug is excreted unchanged in urine.
Primarily renal (80-90% as unchanged drug); minor biliary/fecal elimination (10-20%)
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
10-20% bound, primarily to albumin
20-30% bound to albumin.
0.2-0.3 L/kg, indicating distribution primarily into extracellular fluid
1.6 L/kg; distributes widely into tissues, including erythrocytes and cerebrospinal fluid (with inflamed meninges).
Oral: 75-90%; bioavailability decreases with food intake
Oral: approximately 80% absorbed.
GFR ≥60 m L/min: no adjustment; GFR 30-59: 1350 mg once daily; GFR 15-29: 1350 mg every 48 hours; GFR <15 or dialysis: not recommended.
Cr Cl 30-60 m L/min: 15-20 mg/kg daily; Cr Cl 10-29 m L/min: 15 mg/kg every 24-36 hours; Cr Cl <10 m L/min: 15 mg/kg every 48 hours.
Child-Pugh A: no adjustment; Child-Pugh B: 1350 mg once daily; Child-Pugh C: not recommended.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment.
Not established; safety and efficacy not evaluated.
15-25 mg/kg orally once daily (max 1 g/day for children weighing <20 kg, otherwise 2.5 g/day).
Start at 1350 mg once daily; monitor renal function; increase to twice daily if tolerated and Cr Cl ≥60 m L/min.
Consider reduced initial dose based on renal function; monitor for optic neuritis.
Severe and sometimes fatal hepatitis has been reported with isoniazid. Risk is increased in patients with pre-existing liver disease, daily alcohol use, or concurrent use of other hepatotoxic drugs.
MYAMBUTOL may cause optic neuritis and decreased visual acuity, which may be dose-related and reversible upon discontinuation. Not recommended for use in children under 13 years of age.
Hepatotoxicity (monitor liver function); peripheral neuropathy (pyridoxine supplementation recommended); hypersensitivity reactions; rifampin may cause reddish discoloration of body fluids; drug interactions due to CYP450 induction.
Optic neuritis (monitor visual acuity and color discrimination); hepatic toxicity; renal impairment (dose adjustment required); interaction with aluminum-containing antacids (decreased absorption).
Hypersensitivity to isoniazid, rifampin, or any component; severe hepatic damage; acute liver disease; history of isoniazid-associated hepatotoxicity.
Hypersensitivity to ethambutol; optic neuritis (unless benefit outweighs risk); children under 13 years of age (relative contraindication).
Avoid high-tyramine foods (aged cheeses, cured meats, fermented products) as it may cause hypertensive crisis. Take with food to reduce gastrointestinal upset. Avoid tyramine-rich foods like soy products and sauerkraut.
No significant food interactions. However, administration with food may reduce gastrointestinal upset. Concurrent use with aluminum-containing antacids may decrease absorption; separate by at least 2 hours.
TEEBACIN is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial defects based on animal studies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment due to drug-induced vasoconstriction.
Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant increase in major malformations. However, due to the risk of optic neuritis in the mother, use during pregnancy should be cautious and only if clearly needed.
Unknown if TEEBACIN is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, including immunosuppression and growth retardation, breastfeeding is not recommended. M/P ratio not available.
Ethambutol is excreted into human breast milk in low concentrations; the estimated infant dose is approximately 2-4% of the maternal weight-adjusted dose. The milk-to-plasma ratio is approximately 0.57. The American Academy of Pediatrics considers ethambutol compatible with breastfeeding. Monitor the infant for signs of optic neuritis or gastrointestinal effects.
No dosing recommendations for use in pregnancy as drug is contraindicated. If used inadvertently, pharmacokinetic changes include increased renal clearance in later pregnancy, which may reduce drug exposure. However, due to teratogenicity, no dose adjustment is advised; immediate discontinuation upon pregnancy detection is recommended.
No specific dose adjustments are routinely recommended during pregnancy. However, pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may reduce serum concentrations; therapeutic drug monitoring is not standard but may be considered. Adjust dose based on renal function; usual dose is 15-25 mg/kg/day, not to exceed 2.5 g/day.
Monitor liver function tests (ALT, AST) monthly due to risk of hepatotoxicity. Avoid use in patients with porphyria as it may precipitate acute attacks. Contraindicated in pregnancy (Pregnancy Category X). Administer with pyridoxine (vitamin B6) to reduce peripheral neuropathy risk.
MYAMBUTOL (ethambutol) is a bacteriostatic agent used primarily in combination therapy for tuberculosis. Monitor for optic neuritis, which can cause decreased visual acuity, color blindness, and visual field defects; baseline and monthly visual acuity and color discrimination tests are mandatory. Dose adjustments required in renal impairment (Cr Cl <30 m L/min). Avoid in children <13 years old due to inability to monitor vision. May cause hyperuricemia; monitor uric acid levels in patients with gout.
Take this medication exactly as prescribed; do not skip doses or stop early without consulting your doctor.,Avoid alcohol completely while taking this drug due to increased risk of liver damage.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe nausea/vomiting, or abdominal pain.,Use effective contraception if you are of childbearing age; this drug can cause severe birth defects.,Take vitamin B6 supplements as directed to help prevent numbness or tingling in hands and feet.
Take exactly as prescribed, usually once daily, with or without food.,Report any changes in vision immediately, such as blurred vision, difficulty seeing colors, or blind spots.,Avoid consuming alcohol; may increase risk of liver toxicity.,Do not stop taking this medication even if you feel better; complete full course to prevent resistance.,This drug may cause numbness or tingling in hands or feet; report these symptoms.,Inform your doctor if you have kidney disease, gout, or eye problems before starting treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEEBACIN vs MYAMBUTOL, answered by our medical review team.
TEEBACIN is a Antitubercular agent that works by TEEBACIN is a combination of isoniazid and rifampin. Isoniazid inhibits mycolic acid synthesis in mycobacterial cell wall, while rifampin inhibits bacterial DNA-dependent RNA polymerase.. MYAMBUTOL is a Antitubercular Agent that works by Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEEBACIN and MYAMBUTOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEEBACIN is: 1350 mg orally twice daily with food.. The standard adult dose of MYAMBUTOL is: 15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEEBACIN and MYAMBUTOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEEBACIN is classified as Category C. TEEBACIN is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial de. MYAMBUTOL is classified as Category C. Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.